Tagged: Capitol Hill

2022 Elections Result in Close Races but Less Turnover Than Expected

With mid-term elections serving as a referendum on the party-in-power, Democrats braced for losses and Republicans sought to catch a “red wave” both in New Jersey and nationwide. Although votes are still being counted in some races, both sides can claim victory, as Republicans were able to pick up some seats and Democrats were able to blunt significant Republican gains. New Jersey’s congressional delegation will remain a Democratic majority, as only one of the hotly contested races resulted in an incumbent Democrat’s loss. In New Jersey’s 7th Congressional District, Republican Tom Kean, Jr. and Democrat Tom Malinowski faced off in a rematch of the 2020 election to represent Central Jersey residents. Mr. Malinowski defeated Mr. Kean then by less than 1 percent, but redistricting made the 7th District more Republican. With a more favorable map, Mr. Kean was able to defeat Congressman Malinowski by about 4 percentage points. In the 3rd Congressional District, Democratic incumbent Andy Kim won nearly 55 percent of the vote against Republican challenger Bob Healey. It was unclear if the newly redrawn district would present a challenge for the sitting congressman; however, by midnight, the election returns demonstrated that Mr. Kim was safely re-elected. Other congressional races, such as the contests in the 5th and 11th Districts, were also viewed as...

21st Century Cures Act Lands in Federal Budget Blueprint

President Trump’s proposed FY 2018 Budget (a/k/a the “skinny budget”) presented a departure from his predecessor’s proposed annual budgets – namely a $54 billion increase in defense and military spending paired with corresponding cuts to virtually every other federal department. But one area President Trump did not cut was the implementation of the 21st Century Cures Act (the “Cures Act”), which also happens to be one of the last bills signed into law by then-President Obama. The FY 2018 budget blueprint proposes to appropriate $1.1 billion towards the Cures Act’s implementation in the upcoming fiscal year. The Cures Act strives to expedite the discovery, development, and delivery of new treatments and cures. Those in the medical, biotechnology, and pharmaceutical industry should look to the Cures Act as the potential game-changer that the bipartisan sponsors of the law hoped it would be. Not only does the Cures Act provide the National Institute of Health with significant new funds to speed up research into diseases like cancer and Alzheimer’s, but it also attempts to speed up the process by which new treatments are reviewed and approved by the FDA. The Cures Act also focuses on changes to the treatment of mental health and substance abuse. The reforms included in the Cures Act create a new Assistant Secretary for...

What You Need to Know About Federal Regulatory Reform

President Trump and the newly-elected Congress have made regulatory reform a main focus of their policy agenda. With Republicans controlling both the White House and Capitol Hill for the first time in over a decade, significant actions were taken within the first several weeks of coming into power that regulated industries should be aware of. Implementation of a Regulatory Freeze – The Trump Administration froze all federal rulemaking by issuing a policy memorandum to the Executive Branch departments and agencies. The memorandum declared that no regulations should be submitted “until a department or agency head appointed or designated by the President … reviews and approves the regulation.” The memorandum also required the Executive Branch agencies to either withdraw or postpone all agency regulations submitted to the Office of the Federal Register. The only exceptions to the regulatory freeze are for “emergency situations or other urgent circumstances relating to health, safety, financial, or national security matters” or “regulations subject to statutory or judicial deadlines.” Reducing Regulations for Domestic Manufacturing – President Trump directed the Executive Branch departments and agencies to support the expansion of manufacturing in the United States through “expedited reviews of and approvals for proposals to construct or expand manufacturing facilities and through reductions in regulatory burdens affecting domestic manufacturing.” A key component of...